PUBMED ARTICLES

Humoral immune responses (ELISA, Virus Neutralization, Plaque Reduction, Haemagglutination Inhibition, etc. ) | Cell-mediated immune responses | Prime-boost strategies | Production of hyper immune serum | Longevity of protection | Dose-finding, Dose-optimization | Clinical scoring:
• Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic
• Influenza Intranasal and Intratracheal Challenge.
• Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.
• Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
• Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets.
• A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets.
• Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
• Seasonal influenza vaccine provides priming for A/H1N1 immunization.
• Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.

Prophylaxis and Therapy (delayed treatment) | (Deep) sequencing, mutation-specific PCR | Any route of drug administration possible (IV, oral, nebulizer, etc.) | Read outs include: clinical scoring (signs of disease, body temperature, lung function, etc), viral loads (by quantitative PCR and virus titration), gross pathology, histopathology, immune histochemistry, etc. | Virus transmission:
• Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets.
• New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.
• Delayed oseltamivir treatment of influenza virus A/turkey/Turkey/1/2005 (H5N1) infection in ferrets.

Prophylaxis and Therapy (delayed treatment) | (Deep) sequencing, mutation-specific PCR | Any route of drug administration possible (IV, oral, nebulizer, etc.) | Read outs include: clinical scoring (signs of disease, body temperature, lung function, etc), viral loads (by quantitative PCR and virus titration), gross pathology, histopathology, immune histochemistry, etc.:
• Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques.
• Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.

Active- and passive immunization strategies | Read outs include: antibody responses, cell-mediated immune responses, clinical scoring (signs of disease, body temperature, lung function, etc), viral loads (by quantitative PCR and virus titration), gross pathology, histopathology, immune histochemistry, etc.:
• Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
• Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement.
• Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.
• Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.